Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer
- 31 October 1995
- journal article
- other
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (11) , 1888-1889
- https://doi.org/10.1016/0959-8049(95)00396-z
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Urinary-derived Monocyte-Colony Stimulating Factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC)Annals of Oncology, 1993
- Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.Journal of Clinical Oncology, 1992
- Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.Journal of Clinical Oncology, 1990
- VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials GroupBritish Journal of Cancer, 1988
- Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.Journal of Clinical Oncology, 1987
- Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.Journal of Clinical Oncology, 1987
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982